Tag: Lupin

Company is expanding its diagnostics footprint in East India

The company had posted a net profit of Rs 464 crore in the corresponding quarter last fiscal.

Expanding diagnostics business footprint in North East India

Diana is a senior leader with more than 38 years of field experience in U.S. FDA’s Office of Regulatory Affairs (ORA)

By commercializing cardiometabolic drugs in the Southeast Asian region, Lupin will play a significant role in improving the quality of healthcare

Lupin Diagnostics is also setting up laboratories in West Bengal, Assam, Bihar, Jharkhand and Orissa to comprehensively cater to the East India region

Agreement enables expanded patient access of the only EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders in Central and Eastern European territories

Ramesh Swaminathan, Executive Director, Global CFO & Head Corporate Affairs, Lupin Limited lists his expectations from the budget 2022

The company has established a state-of- the-art 45,000 sq. ft National Reference Laboratory in Navi Mumbai

Innovation, R&D, partnership & policy support to be key growth drivers as echoed at Global Innovation Summit-2021 organized by Indian Pharmaceutical Alliance